Clinical experience with linezolid in infants and children

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue SUPPL. 4, 2011, Pages

  Garazzino, Silvia ^a   Tovo, Pier Angelo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Gram positive bacteria; Off label use; Oxazolidinones; Paediatrics; Tuberculosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CEFADROXIL; CLARITHROMYCIN; COTRIMOXAZOLE; DICLOXACILLIN; ETHAMBUTOL; ETHIONAMIDE; FENTANYL; GAMMA INTERFERON; HEPARIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; LORAZEPAM; METHYLPHENIDATE; OXACILLIN; PYRAZINAMIDE; RETAPAMULIN; RIFAMPICIN; TERIZIDONE; VANCOMYCIN; VENLAFAXINE;

ABDOMINAL PAIN; ACUTE OTITIS MEDIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL ENDOCARDITIS; BACTERIAL MENINGITIS; BACTERIAL SKIN DISEASE; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; BONE INFECTION; BONE MARROW SUPPRESSION; BRAIN ABSCESS; BRAIN VENTRICLE PERITONEUM SHUNT; BRAIN VENTRICULITIS; CANCER PATIENT; CATHETER INFECTION; CELLULITIS; CHILDHOOD DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; DIABETIC PATIENT; DIARRHEA; DRUG CLEARANCE; DRUG COMPETITION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; EPIDURAL ABSCESS; ERADICATION THERAPY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GLOSSITIS; GRAFT RECIPIENT; GRAM POSITIVE INFECTION; GROUPS BY AGE; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; IMPETIGO; INFANT DISEASE; INFECTIOUS ARTHRITIS; INTERVERTEBRAL DISK DEGENERATION; LACTIC ACIDOSIS; LEUKOPENIA; LOOSE FECES; LUNG ABSCESS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEUTROPENIA; NOCARDIA BRASILIENSIS; NOCARDIA FARCINICA; NONHUMAN; OPTIC NERVE DISEASE; OSTEOMYELITIS; PENICILLIN RESISTANCE; PERIPHERAL NEUROPATHY; POLYARTHRITIS; PREMATURITY; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SEROTONIN SYNDROME; SHUNT INFECTION; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS CONSTELLATUS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS MITIS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; SUBDURAL EMPYEMA; THROMBOCYTOPENIA; TOOTH DISCOLORATION; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

ACETAMIDES; ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; OXAZOLIDINONES; TREATMENT OUTCOME;

EID: 79955494020     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr074     Document Type: Review

References (115)

1. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001; 358: 1975-82.
2. Wise R, Andrews JM, Boswell FJ et al. The in vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother 1998; 42: 721-8.
3. Moellering RC Jr. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138: 135-42.
4. Stevens DL, Dotter B, Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2004; 2: 51-9.
5. Wallace RJ Jr, Brown-Elliot BA, Ward SC et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45: 764-7.
6. Herigon J, Hersh AL, Gerber JS et al. Antibiotic management of Staphylococcus aureus infections in US children's hospitals, 1999-2008. Pediatrics 2010; 125: e1294-300.
7. Porta A, Esposito S, Menson E et al. Off-label antibiotic use in children in three European countries. Eur J Clin Pharmacol 2010; 66: 919-27.
8. Pharmacia & Upjohn Company. Zyvox: linezolid injection, linezolid tablets, linezolid for oral suspension package insert. Kalamazoo, MI: Pharmacia & Upjohn Company; 2002.
9. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003; 22: S153-7.
10. Kearns GL, Jungbluth GL, Abdel-Rahman SM et al., for the Pediatric Pharmacology Research Unit Network. Impact of ontogeny on linezolid disposition in neonates and infants. Clin Pharmacol Ther 2003; 74: 413-22.
11. Chiappini E, Conti C, Galli L et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther 2010; 32: 66-88.
12. PhRMA Clinical Study Results Database. http://www.clinicalstudyresults.org (25 Aug 2010, date last accessed).
13. Kaplan SL, Patterson L, Edwards KM et al., for the Linezolid Pediatric Pneumonia Study Group, Pharmacia and Upjohn. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Pediatr Infect Dis J 2001; 20: 488-94.
14. Kaplan SL, Deville JG, Yogev R et al., for the Linezolid Pediatric Study Group. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003; 22: 677-86.
15. Jantausch BA, Deville J, Adler S et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens. Pediatr Infect Dis J 2003; 22: S164-71.
16. Yogev R, Patterson LE, Kaplan SL et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J 2003; 22: S172-7.
17. Deville JG, Adler S, Azimi PH et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J 2003; 22: S158-63.
18. Wible K, Tregnaghi M, Bruss J et al. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr Infect Dis J 2003; 22: 315-22.
19. Kaplan SL, Afghani B, Lopez P et al. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2003; 22: S178-85.
20. Fleishaker DI, Anderson DC, Bruss JB et al. Clinical efficacy of linezolid (LZD) in the treatment of otitis media. Abstracts of the IDSA 38th Annual Meeting. Abstract no. 65. Clin Infect Dis 2000; 31: 224.
21. Protocol M/1260/0082-VRE: Linezolid IV/PO for the treatment of vancomycin-resistant enterococcus infections in children. ClinicalTrials.gov Identifier: NCT00035854. Data on file. http://www.clinicalstudyresults.org/documents/company-study_461_0.pdf (25 Aug 2010, date last accessed).
22. Protocol M12600071/A5951056: Linezolid in the treatment of penicillin resistant Streptococcus pneumoniae pneumonia: an open-label, non-comparator study. ClinicalTrials.gov Identifier: NCT00035269. Data on file. http://www.clinicalstudyresults.org/documents/company-study_459_0.pdf. (25 Aug 2010, date last accessed).
23. Tack K, Ijzerman M, Croos-Dabrera R. Efficacy of linezolid for the treatment of pneumonia caused by penicillin (PRSP) or multi-drug resistant (MDRSP) Streptococcus pneumoniae (SP). Abstract P449. Clin Microbiol Infect 2004; 10 Suppl 3: 93.
24. Ijzerman MM, Cohen MA, Huband MD et al. Antimicrobial activity of linezolid and other agents against nosocomial pneumonia Streptococcus pneumoniae isolates. Abstract P707. Clin Microbiol Infect 2006; 12 Suppl 4-part 3 (P679-P940).
25. Linezolid vs. vancomycin/oxacillin/dicloxacillin in the treatment of catheter-related Gram-positive bloodstream infections. ClinicalTrials.gov identifier: NCT00037050. Data on file. http://www.clinicalstudyresults.org/documents/company-study_1480_0.pdf. (25 Aug 2010, date last accessed).
26. Tack K, Wilcox M, Bouza E et al. Linezolid vs. vancomycin or oxacillin/dicloxacillin for the treatment of catheter-related bloodstream infections (CRSBI). In: Abstracts of the Forty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract K-1748, p. 369. American Society for Microbiology, Washington, DC, USA.
27. Wilcox MH, Tack KJ, Bouza E et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009; 48: 203-12.
28. A randomized, double-blind trial comparing linezolid to vancomycin in the empiric treatment of febrile neutropenic oncology patients with suspected Gram-positive infections. ClinicalTrials.gov identifier: NCT00035425. Data on file. http://www.clinicalstudyresults.org/documents/company-study_904_0.pdf. (25 Aug 2010, date last accessed).
29. Pharmacokinetics of linezolid in children with cystic fibrosis. ClinicalTrials.gov identifier: NCT00625703. http://clinicaltrials.gov/ct2/show/study/NCT00625703 (25 Aug 2010, date last accessed).
30. A randomized, double-blind, double dummy, comparative, multicenter study to assess the safety and efficacy of topical retapamulin ointment, 1%, versus oral linezolid in the treatment of secondarily-infected traumatic lesions and impetigo due to methicillin-resistant Staphylococcus aureus. ClinicalTrials.gov identifier: NCT00852540. http://clinicaltrials.gov/ct2/show/NCT00852540 (25 Aug 2010, date last accessed).
31. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008; 8: 53-66.
32. Beibei L, Yun C, Mengli C et al. Linezolid versus vancomycin for the treatment of gram positive bacterial infections: meta-analysis of randomized controlled trials. Int J Antimicrob Agents 2010; 35: 3-12.
33. Isaacson G, Aronoff SC. Linezolid for tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus and multiple drug resistant Streptococcus pneumonia. Int J Pediatr Otorhinolaryngol 2008; 72: 647-51.
34. Godon N, Denizot S, Podevin G et al. Effectiveness of linezolid and imipenem association in the treatment of severe community-acquired pneumonia in children: two case reports. Scand J Infect Dis 2006; 38: 381-3.
35. Prokop A, Isenberg J, Seifert H et al. Linezolid-a new antibiotic for treatment of methicillin-resistant Staphylococcus aureus infections in trauma surgery? Report of 2 cases [in German]. Unfallchirurg 2002; 105: 287-91.
36. Gales AC, Sader HS, Andrade SS et al. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agent 2006; 27: 300-2.
37. Malacarne P, Viaggi B, Di Paolo A et al. Linezolid cerebrospinal fluid concentration in central nervous system infection. J Chemother 2007; 19: 90-3.
38. Yogev R, Damle B, Levy G et al. Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents. Pediatr Infect Dis J 2010; 29: 827-30.
39. Yilmaz A, Dalgic N, Müslüman M et al. Linezolid treatment of shunt-related cerebrospinal fluid infections in children. J Neurosurg Pediatr 2010; 5: 443-8.
40. Graham PL, Ampofo K, Saiman L. Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis. Pediatr Infect Dis J 2002; 21: 798-9.
41. Maranich AM, Rajnik M. Successful treatment of vancomycin-resistant enterococcal ventriculitis in a pediatric patient with linezolid. Mil Med 2008; 173: 927-9.
42. Baysallar M, Izci Y, Kilic A et al. A case of ventricular drainage infection with a rare pathogen in cerebrospinal fluid: vancomycin-resistant Enterococcus faecium. Microb Drug Resist 2006; 12: 59-62.
43. da Silva PS, Monteiro Neto H, Sejas LM. Successful treatment of vancomycin-resistant enterococcus ventriculitis in a child. Braz J Infect Dis 2007; 11: 297-9.
44. Kumar S, Kohlhoff S, Valencia G et al. Treatment of vancomycin-resistant Enterococcus faecium ventriculitis in a neonate. Int J Antimicrob Agents 2007; 29: 740-1.
45. Dinleyici EC, Yarar C, Dinleyici M et al. Successful treatment with linezolid of meningitis complicated with subdural empyema in a 6-month-old boy. J Trop Pediatr 2007; 53: 431-3.
46. Anil M, Ozkalay N, Helvaci M et al. Meningitis due to Gemella haemolysans in a pediatric case. J Clin Microbiol 2007; 45: 2337-9.
47. Al Kandari M, Jamal W, Udo EE et al. A case of community-onset meningitis caused by hospital methicillin-resistant Staphylococcus aureus successfully treated with linezolid and rifampicin. Med Princ Pract 2010; 19: 235-9.
48. Milstone AM, Dick J, Carson B et al. Cerebrospinal fluid penetration and bacteriostatic activity of linezolid against Enterococcus faecalis in a child with a ventriculoperitoneal shunt infection. Pediatr Neurosurg 2007; 43: 406-9.
49. Cook AM, Ramsey CN, Martin CA et al. Linezolid for the treatment of a heteroresistant Staphylococcus aureus shunt infection. Pediatr Neurosurg 2005; 41: 102-4.
50. Vigano' SM, Edefonti A, Ferraresso M et al. Successful medical treatment of multiple brain abscesses due to Nocardia farcinica in a paediatric renal transplant recipient. Pediatr Nephrol 2005; 20: 1186-8.
51. Lefebvre L, Metellus P, Dufour H et al. Linezolid for treatment of subdural empyema due to Streptococcus: case reports. Surg Neurol 2009; 71: 89-91.
52. Gallagher RM, Pizer B, Ellison JA et al. Glycopeptide insensitive Staphylococcus aureus subdural empyema treated with linezolid and rifampicin. J Infect 2008; 57: 410-3.
53. Sabbatani S, Manfredi R, Frank G et al. Linezolid in the treatment of severe central nervous system infections resistant to recommended antimicrobial compounds. Infez Med 2005; 13: 112-9.
54. Lackner P, Beer R, Broessner G et al. Acute granulomatous acanthamoeba encephalitis in an immunocompetent patient. Neurocrit Care 2010; 12: 91-4.
55. Moylett EH, Pacheco SE, Brown-Elliott BA et al. Clinical experience with linezolid for the treatment of Nocardia infection. Clin Infect Dis 2003; 36: 313-8.
56. Sullivan J, Tobias JD. Preliminary experience with the use of oral linezolid in infants for the completion of antibiotic therapy in the outpatient setting after admission to the pediatric intensive care unit. Am J Ther 2006; 13: 473-7.
57. Rao N, Hamilton CW. Efficacy and safety of linezolid for gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis 2007; 59: 173-9.
58. Nguyen S, Pasquet A, Legout L et al. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 2009; 15: 1163-9.
59. Chen CJ, Chiu CH, Lin TY et al. Experience with linezolid therapy in children with osteoarticular infections. Pediatr Infect Dis J 2007; 26: 985-8.
60. Javaheri M, Khurana RN, O'Hearn TM et al. Linezolid-induced optic neuropathy: a mitochondrial disorder? Br J Ophthalmol 2007; 91: 111-5.
61. Krzysztofiak A, Pagnotta G, Lancella L et al. Linezolid therapy for pediatric thoracic spondylodiscitis due to Staphylococcus aureus sepsis. Int J Infect Dis 2009; 14 Suppl 3: e205-7.
62. Linam WM, Wesselkamper K, Gerber MA. Peripheral neuropathy in an adolescent treated with linezolid. Pediatr Infect Dis J 2009; 28: 149-51.
63. Beach HD, Valeron N, Yves-Rene Linares M. Twenty-month-old patient with distal humerus fracture and concomitant septic arthritis. Pediatr Emerg Care 2010; 26: 132-3.
64. Ma JS. Teeth and tongue discoloration during linezolid therapy. Pediatr Infect Dis J 2009; 28: 345-6.
65. Travaglianti M, Pérez M, Sberna N et al. Treatment of vancomycinresistant Enterococcus with linezolid in paediatric hospitals. Farm Hosp 2007; 31: 43-7.
66. Hoehn R, Groll AH, Schaefer V et al. Linezolid treatment of glycopeptide-resistant Enterococcus faecium in very low birth weight premature neonates. Int J Antimicrob Agents 2006; 27: 256-8.
67. Klingkowski U, Huth RG, Habermehl P et al. Linezolid in two premature babies with necrotizing enterocolitis and infection with vancomycin-resistant enterococcus [in German]. Klin Padiatr 2004; 216: 21-3.
68. Langgartner M, Mutenthaler A, Haiden N et al. Linezolid for treatment of catheter-related cerebrospinal fluid infections in preterm infants. Arch Dis Child Fetal Neonatal Ed 2008; 93: F397.
69. Ergaz Z, Arad I, Bar-Oz B et al. Elimination of vancomycin-resistant enterococci from a neonatal intensive care unit following an outbreak. J Hosp Infect 2010; 74: 370-6.
70. Moschovi M, Trimis G, Tsotra M et al. Efficacy and safety of linezolid in immunocompromised children with cancer. Pediatr Int 2010; 52: 694-8.
71. Garazzino S, Krzysztofiak A, Castagnola E et al. Clinical experience with linezolid in infants and children: a multicenter study of the Italian Society for Pediatric Infectious Diseases (SITIP). In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract G-911, p. 96. American Society for Microbiology, Washington, DC, USA.
72. Ang JY, Lua JL, Turner DR et al. Vancomycin-resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid. Pediatr Infect Dis J 2003; 22: 1101-3.
73. Sung TJ, Kim HM, Kim MJ. Methicillin-resistant Staphylococcus aureus endocarditis in an extremely low-birth-weight infant treated with linezolid. Clin Pediatr (Phila) 2008; 47: 504-6.
74. Taketani T, Kanai R, Fukuda S et al. Pure red cell precursor toxicity by linezolid in a pediatric case. J Pediatr Hematol Oncol 2009; 31: 684-6.
75. Chi CY, Lauderdale TL, Wang SM et al. Health care-associated endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. J Clin Microbiol 2008; 46: 810-3.
76. Tavil B, Balci YI, Yildirim I et al. Linezolid-induced reversible bicytopenia in a 4-year-old boy with methicillin-resistant Staphylococcus aureus bacteremia. Pediatr Hematol Oncol 2008; 25: 67-71.
77. Ng PC, Chow VC, Lee CH et al. Persistent Staphylococcus capitis septicemia in a preterm infant. Pediatr Infect Dis J 2006; 25: 652-4.
78. Castagnola E, Moroni C, Gandullia P et al. Catheter lock and systemic infusion of linezolid for treatment of persistent Broviac catheter-related staphylococcal bacteremia. Antimicrob Agents Chemother 2006; 50: 1120-1.
79. Brennan K, Jones BL, Jackson L. Auditory nerve neuropathy in a neonate after linezolid treatment. Pediatr Infect Dis J 2009; 28: 169.
80. Matson KL, Miller SE. Tooth discoloration after treatment with linezolid. Pharmacotherapy 2003; 23: 682-5.
81. Knorr JP, Moshfeghi M, Sokoloski MC. Ciprofloxacin-induced Q-T interval prolongation. Am J Health Syst Pharm 2008; 65: 547-51.
82. Bruns AS, Sood N. Community-acquired methicillin-resistant Staphylococcus aureus epidural abscess with bacteremia and multiple lung abscesses: case report. Am J Crit Care 2009; 18: 86-7.
83. Valentini P, Parisi G, Monaco M et al. An uncommon presentation for a severe invasive infection due to methicillin-resistant Staphylococcus aureus clone USA300 in Italy: a case report. Ann Clin Microbiol Antimicrob 2008; 7: 11.
84. Alcala' L, Ruiz-Serrano MJ, Pérez-Fernández Turégano C et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 2003; 47: 416-7.
85. Erturan Z, Uzun M. In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 2005; 26: 78-80.
86. Fortun J, Martin-Davila P, Navas E et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56: 180-5.
87. Von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)-a report of ten cases. J Infect 2006; 52: 92-6.
88. Nam HS, Koh WJ, Kwon OJ et al. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Int J Antimicrob Agents 2009; 33: 92-3.
89. Schecter GF, Scott C, True L et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50: 49-55.
90. Park IN, Hong SB, Oh YM et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006; 58: 701-4.
91. Migliori GB, Eker B, Richardson MD et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-93.
92. Koh WJ, Kwon OJ, Gwak H et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64: 388-91.
93. Anger HA, Dworkin F, Sharma S et al. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother 2010; 65: 775-83.
94. Condos R, Hadgiangelis N, Leibert E et al. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008; 134: 187-92.
95. Schaaf HS, Willemse M, Donald PR. Long-term linezolid treatment in a young child with extensively drug-resistant tuberculosis. Pediatr Infect Dis J 2009; 28: 748-50.
96. Thorell EA, Sharma M, Jackson MA et al. Disseminated nontuberculous mycobacterial infections in sickle cell anemia patients. J Pediatr Hematol Oncol 2006; 28: 678-81.
97. Kloss P, Xiong L, Shinabarger DL et al. Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999; 294: 93-101.
98. Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann Pharmacother 2003; 37: 769-74.
99. Meka VG, Pillai SK, Sakoulas G et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 2004; 190: 311-7.
100. Roberts SM, Freeman AF, Harrington SM et al. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr Infect Dis J 2006; 25: 562-4.
101. Hill R, Kearns A, Nash J et al. Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. J Antimicrob Chemother 2010; 65: 442-5.
102. Verma N, Clarke RW, Bolton-Maggs PH et al. Gut overgrowth of vancomycin-resistant enterococci (VRE) results in linezolid-resistant mutation in a child with severe congenital neutropenia: a case report. J Pediatr Hematol Oncol 2007; 29: 557-60.
103. Fossati M, Cappelli B, Biral E et al. Fatal vancomycin- and linezolid-resistant Enterococcus faecium sepsis in a child undergoing allogeneic haematopoietic stem cell transplantation for beta-thalassemia major. J Med Microbiol 2010; 59: 839-42.
104. Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect 2009; 59: S59-74.
105. Saiman L, Goldfarb J, Kaplan SA et al. Safety and tolerability of linezolid in children. Pediatr Infect Dis J 2003; 22: S193-200.
106. Meissner HC, Townsend T, Wenman W. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003; 22: S186-92.
107. Thomas CR, Rosenberg M, Blythe V et al. Serotonin syndrome and linezolid. J Am Acad Child Adolesc Psychiatry 2004; 43: 790.
108. Hammerness P, Parada H, Abrams A et al. Linezolid: MAOI activity and potential drug interactions. Psychosomatics 2002; 43: 248-9.
109. Clancy MJ, Graepler A, Breese PE et al. Widespread emergence of methicillin resistance in community-acquired Staphylococcus aureus infections in Denver. South Med J 2005; 98: 1069-75.
110. Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community-and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290: 2976-84.
111. Salmenlinna S, Lyytiküinen O, Vuopio-Varkila J. Community-acquired methicillin-resistant Staphylococcus aureus, Finland. Emerg Infect Dis 2002; 8: 602-7.
112. Sattler CA, Mason EO Jr, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 2002; 21: 910-7.
113. Velissariou IM. Use of linezolid in neonates and children: an overview of recent advances. Expert Rev Anti Infect Ther 2006; 4: 947-52.
114. Dotis J, Iosifidis E, Ioannidou M et al. Use of linezolid in pediatrics: a critical review. Intl J Infect Dis 2010; 14: e638-48.
115. Kocher S, Müller W, Resch B. Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review. Int J Antimicrob Agents 2010; 36: 106-10.